Recent Treatment Strategies for Polycystic Ovary Syndrome

Hyejin Lee

doi:10.4093/jkd.2015.16.3.194

Journal List > J Korean Diabetes > v.16(3) > 1054975

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee: Recent Treatment Strategies for Polycystic Ovary Syndrome

Focused Issue

J Korean Diabetes 2015;16(3):194-197.

Published online: 10 January 2015

DOI: https://doi.org/10.4093/jkd.2015.16.3.194

Recent Treatment Strategies for Polycystic Ovary Syndrome

Hyejin Lee

Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea

Corresponding author: Hyejin Lee Department of Internal Medicine, Ewha Womans University School of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea, E-mail: hyejinlee@ewha.ac.kr

Received 24 July 2015 Accepted 19 August 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-aged women. This syndrome is characterized by its heterogeneous presentation including oligoovulation, hyperandrogenism and polycystic ovary morphology. Moreover, women with PCOS exhibit metabolic dysfunction and have an increased risk of type 2 diabetes mellitus. The treatment approach is dependent on the presenting phenotype. Hormonal contraceptives are the first-line management for menstrual abnormalities and androgen excess symptoms, whereas clomiphene is the first-line therapy for infertility. Metformin is beneficial for metabolic abnormalities and menstrual irregularities.

Keywords: Androgen, Management, Polycystic ovary syndrome

References

1. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009; 92:1966–82.

2. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 2003; 79:956–62.

3. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, longterm clinical evaluation. J Clin Endocrinol Metab. 2000; 85:139–46.

4. Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action–a hypothesis revisited. Fertil Steril. 1984; 42:331–44.

5. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. BMJ. 2003; 327:951–3.

6. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER. Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007; 356:551–66.

7. Polyzos NP, Tsappi M, Mauri D, Atay V, Cortinovis I, Casazza G. Aromatase inhibitors for infertility in polycystic ovary syndrome. The beginning or the end of a new era? Fertil Steril. 2008; 89:278–80.

8. Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: a prospective randomized trial. J Hum Reprod Sci. 2012; 5:262–5.

9. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006; 19:210–23.

10. Givens JR, Andersen RN, Wiser WL, Fish SA. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J Clin Endocrinol Metab. 1974; 38:727–35.

11. Wild RA, Umstot ES, Andersen RN, Givens JR. Adrenal function in hirsutism. II. Effect of an oral contraceptive. J Clin Endocrinol Metab. 1982; 54:676–81.

12. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98:4565–92.

13. Neumann F, Berswordt-Wallrabe R VO, Elger W, Steinbeck H, Hahn JD, Kramer M. Aspects of androgen-dependent events as studied by antiandrogens. Recent Prog Horm Res. 1970; 26:337–410.

14. Shapiro G, Evron S. A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab. 1980; 51:429–32.

15. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000; 52:595–600.

16. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A metaanalysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006; 12:673–83.

17. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J, Mavrikakis M. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005; 152:749–56.

18. Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA, Makrigiannakis A, Katsouras CS, Chrousos GP, Tsatsoulis A, Michalis LK. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2011; 95:203–9.

19. Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a metaanalysis of randomized controlled trials. Exp Clin Endocrinol Diabetes. 2012; 120:367–75.

TOOLS

Similar articles